Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2017 06:02 ET | Source: AC Immune SA

Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference

Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer PI-2620 at the International Conference on Alzheimer's and Parkinson's Diseases and Related...
March 23, 2017 11:58 ET | Source: AC Immune SA

AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE at the International Conference on Alzheimer's and Parkinson's Diseases Lausanne, Switzerland, March 23, 2017 - AC...
March 17, 2017 06:36 ET | Source: AC Immune SA

AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE

AC IMMUNE reports Full year 2016 financial results and R&D update Strong cash position of CHF 152.2 million provides resources to advance pipeline of seven therapeutic and three...
February 28, 2017 02:01 ET | Source: AC Immune SA

AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB

Strong commitment to potential disease-modifying therapy New Phase 3 CREAD2 trial to investigate 750 participants Current Phase 3 CREAD1 trial of 750 participants expected to read out 2020 ...
December 09, 2016 15:49 ET | Source: AC Immune SA

AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB

AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB Crenezumab higher dose in CREAD Phase 3 Alzheimer's trial supported by exposure-response model Phase 1b...
November 23, 2016 09:32 ET | Source: AC Immune SA

AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER

Lausanne, Switzerland, November 23, 2016 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today...
November 15, 2016 07:06 ET | Source: AC Immune SA

AC Immune SA announces results of annual general meeting

AC Immune Announces Results of Annual General Meeting Financial expert Mr. Thomas Graney elected as new member of the Board of Directors Shareholders approve all proposed resolutions of the...
November 11, 2016 07:12 ET | Source: AC Immune SA

AC Immune Reports Third Quarter 2016 Results

LAUSANNE, Switzerland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced...
November 11, 2016 06:35 ET | Source: AC Immune SA

AC Immune SA Reports Third Quarter 2016 Results

AC Immune Reports Third Quarter 2016 Results Successfully Completed Initial Public Offering on NASDAQ, Net Proceeds of $ 70.5 million (CHF 69.4 million)* Lausanne, Switzerland,...
September 23, 2016 01:42 ET | Source: AC Immune SA

Switzerland's AC Immune Opens For Trading On NASDAQ

SWITZERLAND'S AC IMMUNE OPENS FOR TRADING ON NASDAQ LAUSANNE, Switzerland, Sept. 23, 2016 (GLOBE NEWSWIRE) -- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on...